<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00115778</url>
  </required_header>
  <id_info>
    <org_study_id>AAAB0431</org_study_id>
    <nct_id>NCT00115778</nct_id>
  </id_info>
  <brief_title>Intravenous Immunoglobulin (IVIG) in Lung Transplantation</brief_title>
  <official_title>IVIG for Acquired Immunodeficiency in Lung Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arcasoy, Selim, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Grifols Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Arcasoy, Selim, M.D.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if intravenous immunoglobulin (IVIG) can prevent
      bacterial infections in lung transplant patients with low serum levels of immunoglobulin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An increased risk of infection despite intensive antimicrobial prophylaxis is a
      well-recognized complication of lung transplantation. Recent evidence suggests that
      immunosuppressive therapy after solid organ transplantation may lead to humoral
      immunodeficiency due to hypogammaglobulinemia (HGG). In lung transplant recipients with HGG,
      IVIG therapy offers the potential to significantly decrease the incidence and severity of
      infections, thereby reducing morbidity and potentially mortality.

      Comparison: The investigators are conducting a randomized clinical trial of IVIG versus
      placebo for lung transplant patients with severe HGG to see if IVIG decreases the number of
      bacterial infections in these patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2005</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bacterial infections</measure>
    <time_frame>3 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other infections</measure>
    <time_frame>3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital admissions</measure>
    <time_frame>3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibiotic use</measure>
    <time_frame>3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms</measure>
    <time_frame>3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function</measure>
    <time_frame>3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rejection</measure>
    <time_frame>3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>3 month</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hypogammaglobulinemia</condition>
  <condition>Lung Transplantation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous immunoglobulin</intervention_name>
    <description>Intravenous immunoglogbulin 400mg/kg IV monthly</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Lung transplant recipients &gt;3 months after transplant surgery

          -  IgG &lt; 500 mg/dL

          -  Stable medical regimen

        Exclusion Criteria:

          -  Acute rejection

          -  Active infection

          -  Contraindication to IVIG

          -  Pregnancy

          -  Recent thrombotic event
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Selim M Arcasoy, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York Presbyterian Hospital Lung Transplant Program</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2005</study_first_submitted>
  <study_first_submitted_qc>June 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2005</study_first_posted>
  <last_update_submitted>June 18, 2009</last_update_submitted>
  <last_update_submitted_qc>June 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>Selim Arcasoy, MD</name_title>
    <organization>Columbia Unversity</organization>
  </responsible_party>
  <keyword>Hypogammaglobulinemia</keyword>
  <keyword>Lung Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Agammaglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>June 14, 2011</submitted>
    <returned>July 12, 2011</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

